Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY.

Cancer Cell. 2019 Jan 14;35(1):33-45.e6. doi: 10.1016/j.ccell.2018.12.001.

PMID:
30645975
2.

E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.

Tarhini AA, Lee SJ, Li X, Rao UNM, Nagarajan A, Albertini MR, Mitchell JW Jr, Wong SJ, Taylor MA, Laudi N, Truong PV, Conry RM, Kirkwood JM.

Clin Cancer Res. 2019 Jan 15;25(2):524-532. doi: 10.1158/1078-0432.CCR-18-2258. Epub 2018 Nov 12.

PMID:
30420448
3.

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM.

J Clin Oncol. 2018 Oct 25:JCO1800632. doi: 10.1200/JCO.18.00632. [Epub ahead of print]

PMID:
30359157
4.

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.

Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, Butterfield LH, McDermott D, Chen A, Lara PN, Kirkwood JM.

Cancer. 2018 Nov 15;124(22):4332-4341. doi: 10.1002/cncr.31734. Epub 2018 Oct 10.

PMID:
30303516
5.

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.

Retseck J, Nasr A, Lin Y, Lin H, Mendiratta P, Butterfield LH, Tarhini AA.

J Transl Med. 2018 Jul 4;16(1):184. doi: 10.1186/s12967-018-1563-y.

6.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

7.

Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi.

Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM.

Cancer Prev Res (Phila). 2018 Jul;11(7):429-438. doi: 10.1158/1940-6207.CAPR-17-0268. Epub 2018 Apr 24.

PMID:
29691233
8.

Using Genomic Sequencing to Improve Management in Melanoma.

Funchain P, Tarhini AA.

Oncology (Williston Park). 2018 Mar 15;32(3):98-101, 104.

9.

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.

Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, Tawbi HA.

J Immunother Cancer. 2017 Sep 19;5(1):74. doi: 10.1186/s40425-017-0279-5.

10.

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.

Tarhini AA, Floros T, Lin HM, Lin Y, Rahman Z, Ashraf M, Vallabhaneni P, Sander C, Rao UNM, Panelli M, LaFramboise WA, Kirkwood JM.

Melanoma Res. 2017 Oct;27(5):429-438. doi: 10.1097/CMR.0000000000000383. Erratum in: Melanoma Res. 2018 Dec;28(6):655. LaFramboise, William F [corrected to LaFramboise, William A].

11.

Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy.

Tarhini AA, Lorigan P, Leachman S.

Am Soc Clin Oncol Educ Book. 2017;37:651-660. doi: 10.14694/EDBK_174930. Review.

12.

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).

Butterfield LH, Zhao F, Lee S, Tarhini AA, Margolin KA, White RL, Atkins MB, Cohen GI, Whiteside TL, Kirkwood JM, Lawson DH.

Clin Cancer Res. 2017 Sep 1;23(17):5034-5043. doi: 10.1158/1078-0432.CCR-16-3016. Epub 2017 May 23.

13.

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.

Tarhini AA, Moschos SJ, Lin Y, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM.

Melanoma Res. 2017 Aug;27(4):342-350. doi: 10.1097/CMR.0000000000000353.

PMID:
28489678
14.

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM.

Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. Epub 2017 May 4.

15.

The use of immunotherapy in the treatment of melanoma.

Achkar T, Tarhini AA.

J Hematol Oncol. 2017 Apr 24;10(1):88. doi: 10.1186/s13045-017-0458-3. Review.

16.

Adjuvant Therapy for Melanoma.

Agha A, Tarhini AA.

Curr Oncol Rep. 2017 May;19(5):36. doi: 10.1007/s11912-017-0594-5. Review.

PMID:
28417343
17.

Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit.

Tarhini AA, Lin Y, Lin HM, Vallabhaneni P, Sander C, LaFramboise W, Hamieh L.

Oncoimmunology. 2016 Sep 19;6(2):e1231291. doi: 10.1080/2162402X.2016.1231291. eCollection 2017.

18.

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

Kalinsky K, Lee S, Rubin KM, Lawrence DP, Iafrarte AJ, Borger DR, Margolin KA, Leitao MM Jr, Tarhini AA, Koon HB, Pecora AL, Jaslowski AJ, Cohen GI, Kuzel TM, Lao CD, Kirkwood JM.

Cancer. 2017 Jul 15;123(14):2688-2697. doi: 10.1002/cncr.30663. Epub 2017 Mar 23.

19.

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.

Najjar YG, Ding F, Lin Y, VanderWeele R, Butterfield LH, Tarhini AA.

J Transl Med. 2017 Feb 21;15(1):39. doi: 10.1186/s12967-017-1140-9.

20.

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM.

J Clin Oncol. 2017 Mar 10;35(8):885-892. doi: 10.1200/JCO.2016.70.2951. Epub 2017 Jan 30.

21.

Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery.

Kano H, Morales-Restrepo A, Iyer A, Weiner GM, Mousavi SH, Kirkwood JM, Tarhini AA, Flickinger JC, Lunsford LD.

J Neurosurg. 2018 Jan;128(1):14-22. doi: 10.3171/2016.9.JNS161011. Epub 2017 Jan 20.

PMID:
28106495
22.

Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma.

Tarhini AA, Tawbi H, Storkus WJ.

Melanoma Manag. 2016 Dec;3(4):251-254. doi: 10.2217/mmt-2016-0016. Epub 2016 Nov 29. No abstract available.

23.

Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.

Retseck J, VanderWeele R, Lin HM, Lin Y, Butterfield LH, Tarhini AA.

J Immunother Cancer. 2016 Jun 21;4:38. doi: 10.1186/s40425-016-0141-1. eCollection 2016.

24.

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):632-46. doi: 10.1016/j.ijrobp.2016.01.038. Review. Erratum in: Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):486.

25.

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients.

Mehta K, Appleman L, Wang H, Tarhini AA, Parikh RA.

PLoS One. 2016 Jan 22;11(1):e0147153. doi: 10.1371/journal.pone.0147153. eCollection 2016.

26.

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.

Tarhini AA, Zahoor H, Yearley JH, Gibson C, Rahman Z, Dubner R, Rao UN, Sander C, Kirkwood JM.

J Transl Med. 2015 Sep 30;13:319. doi: 10.1186/s12967-015-0678-7.

27.

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.

Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, Kirkwood JM.

J Immunother Cancer. 2015 Sep 15;3:39. doi: 10.1186/s40425-015-0081-1. eCollection 2015.

28.

Neoadjuvant therapy in melanoma: the fast track to critical new answers.

Tarhini AA.

Clin Adv Hematol Oncol. 2015 Aug;13(8):510-1. No abstract available.

PMID:
26351812
30.

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.

Floros T, Tarhini AA.

Semin Oncol. 2015 Aug;42(4):539-48. doi: 10.1053/j.seminoncol.2015.05.015. Epub 2015 Jun 3. Review.

31.

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.

Tarhini AA, Lin Y, Zahoor H, Shuai Y, Butterfield LH, Ringquist S, Gogas H, Sander C, Lee S, Agarwala SS, Kirwood JM.

PLoS One. 2015 Jul 20;10(7):e0132745. doi: 10.1371/journal.pone.0132745. eCollection 2015.

32.

Still Leading the Charge in Immunotherapy.

Tarhini AA.

Oncology (Williston Park). 2015 Jul;29(7):501-2. No abstract available.

33.

Immunotherapy of Melanoma.

Tarhini AA.

Curr Mol Pharmacol. 2016;9(3):196-207. Review.

PMID:
26177647
34.

Neoadjuvant therapy for melanoma: a promising therapeutic approach and an ideal platform in drug development.

Tarhini AA.

Am Soc Clin Oncol Educ Book. 2015:e535-42. doi: 10.14694/EdBook_AM.2015.35.e535. Review.

35.

Immune checkpoint blockade and interferon-α in melanoma.

Rafique I, Kirkwood JM, Tarhini AA.

Semin Oncol. 2015 Jun;42(3):436-47. doi: 10.1053/j.seminoncol.2015.02.012. Epub 2015 Feb 14. Review.

36.

Intermediate-grade meningeal melanocytoma associated with nevus of Ota: a case report and review of the literature.

Shin D, Sinha M, Kondziolka DS, Kirkwood JM, Rao UN, Tarhini AA.

Melanoma Res. 2015 Aug;25(4):273-8. doi: 10.1097/CMR.0000000000000163. Review.

PMID:
25933209
37.

Melanoma adjuvant therapy.

Thalanayar PM, Agarwala SS, Tarhini AA.

Chin Clin Oncol. 2014 Sep;3(3):26. doi: 10.3978/j.issn.2304-3865.2014.03.02.

38.

The future of systemic therapy of melanoma: combinations, predictive biomarkers.

Tarhini AA.

Oncology (Williston Park). 2015 Feb;29(2):94, 107. No abstract available.

39.

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM.

JAMA. 2014 Nov 5;312(17):1744-53. doi: 10.1001/jama.2014.13943.

40.

Melanoma adjuvant therapy.

Tarhini AA, Thalanayar PM.

Hematol Oncol Clin North Am. 2014 Jun;28(3):471-89. doi: 10.1016/j.hoc.2014.02.004. Review.

PMID:
24880942
41.

Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa.

Tarhini AA, Shin D, Lee SJ, Stuckert J, Sander CA, Kirkwood JM.

Melanoma Res. 2014 Apr;24(2):150-7. doi: 10.1097/CMR.0000000000000050.

42.

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.

Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN, Kirkwood JM.

PLoS One. 2014 Feb 3;9(2):e87705. doi: 10.1371/journal.pone.0087705. eCollection 2014.

43.

A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.

Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, Lee S, Kirkwood JM.

J Transl Med. 2014 Jan 23;12:19. doi: 10.1186/1479-5876-12-19.

44.

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM.

Cancer Res. 2014 Feb 15;74(4):1045-55. doi: 10.1158/0008-5472.CAN-13-2908. Epub 2013 Dec 16.

45.

Advances in adjuvant therapy: potential for prognostic and predictive biomarkers.

Davar D, Tarhini AA, Gogas H, Kirkwood JM.

Methods Mol Biol. 2014;1102:45-69. doi: 10.1007/978-1-62703-727-3_4. Review.

PMID:
24258973
46.

The accuracy of predicting survival in individual patients with cancer.

Kondziolka D, Parry PV, Lunsford LD, Kano H, Flickinger JC, Rakfal S, Arai Y, Loeffler JS, Rush S, Knisely JP, Sheehan J, Friedman W, Tarhini AA, Francis L, Lieberman F, Ahluwalia MS, Linskey ME, McDermott M, Sperduto P, Stupp R.

J Neurosurg. 2014 Jan;120(1):24-30. doi: 10.3171/2013.9.JNS13788. Epub 2013 Oct 25.

PMID:
24160479
47.

Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.

Tarhini AA, Zahoor H, McLaughlin B, Gooding WE, Schmitz JC, Siegfried JM, Socinski MA, Argiris A.

Anticancer Res. 2013 Oct;33(10):4475-81.

48.

ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).

Go RS, Lee SJ, Shin D, Callister SM, Jobe DA, Conry RM, Tarhini AA, Kirkwood JM.

Clin Cancer Res. 2013 Dec 1;19(23):6597-604. doi: 10.1158/1078-0432.CCR-13-1414. Epub 2013 Oct 11.

49.

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.

Ramalingam SS, Kotsakis A, Tarhini AA, Heron DE, Smith R, Friedland D, Petro DP, Raez LE, Brahmer JR, Greenberger JS, Dacic S, Hershberger P, Landreneau RJ, Luketich JD, Belani CP, Argiris A.

Lung Cancer. 2013 Sep;81(3):416-21. doi: 10.1016/j.lungcan.2013.06.002. Epub 2013 Jul 10.

PMID:
23849982
50.

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2013 Jun 3;11:137. doi: 10.1186/1479-5876-11-137.

Supplemental Content

Loading ...
Support Center